Orantinib

Drug Overview

Orantinib (also known by its developmental codes TSU-68 and SU6668) is an orally bioavailable, small-molecule, multitargeted receptor tyrosine kinase inhibitor (TKI). It belongs to the indolinone class of compounds and is specifically engineered to target and inhibit the signaling of three critical growth factor receptors: the Vascular Endothelial Growth Factor Receptor (VEGFR), the Platelet-Derived Growth Factor Receptor (PDGFR), and the Fibroblast Growth Factor Receptor (FGFR).

In the clinical landscape of March 2026, orantinib is recognized as a potent “anti-angiogenic” agent with a specialized role in treating hypervascular tumors. While many first-generation TKIs primarily target one or two pathways, orantinib’s “triple-threat” mechanism allows it to simultaneously block the blood supply to a tumor, prevent the tumor from recruiting support cells, and stop the tumor from growing directly. This makes it a significant area of research in hepatocellular carcinoma (HCC) and other solid tumors that have become resistant to standard-of-care treatments like sorafenib or lenvatinib. Developed by Taiho Pharmaceutical and originally explored by Sugen, orantinib continues to be a subject of intense study for its ability to overcome the “growth factor escape” that many cancers use to survive.

• Generic Name: Orantinib.
• Code Names: TSU-68, SU6668.
• Drug Class: Multitargeted Tyrosine Kinase Inhibitor (TKI); Anti-angiogenic Agent.
• Mechanism: Competitive inhibition of ATP binding to VEGFR-2, PDGFR-β, and FGFR-1.
• Route of Administration: Oral (Tablet).
• FDA Approval Status: Investigational. As of March 2026, it is not FDA-approved. It has been evaluated in numerous Phase 2 and Phase 3 trials, particularly in Asian populations for liver cancer, and remains available through specific clinical research protocols.

What Is It and How Does It Work? (Mechanism of Action)

Orantinib works by surgically “cutting off” the infrastructure the cancer cell needs to survive. It targets the “building blocks” of a tumor’s life-support system.

1. Inhibiting Angiogenesis (The “Starvation” Strategy)

Most of orantinib’s power comes from blocking VEGFR-2.

• The Blood Supply: Tumors need a constant supply of fresh blood to grow. They release a protein called VEGF to “call” for new blood vessels to grow toward them.
• The Blockade: Orantinib sits in the “lock” of the VEGFR-2 receptor. This prevents the tumor’s “call” from being heard, causing existing tumor vessels to wither and preventing new ones from forming.

2. Disrupting Support Cells (The “Pericyte” Strategy)

By targeting PDGFR-β, orantinib attacks the cells that protect blood vessels.

• Pericytes: These cells act as “scaffolding” or “armor” for the tumor’s blood vessels, making them tough and hard to destroy.
• The Result: When orantinib blocks PDGFR, these support cells fall away, leaving the tumor’s blood vessels fragile and more vulnerable to chemotherapy or the body’s own immune system.

3. Preventing Resistance (The “Escape” Strategy)

The most unique feature of orantinib is its inhibition of FGFR-1.

• The Backup Plan: Many cancers, when their VEGF blood supply is blocked, “switch” to using FGF as a backup growth signal. This is why many drugs stop working after a few months.
• Closing the Door: By blocking FGFR at the same time as VEGFR and PDGFR, orantinib theoretically prevents the cancer from finding a “workaround,” leading to a more durable treatment effect.

Clinical Indications and Research Status (2026)

In 2026, orantinib is primarily being evaluated in cancers that are known for having high blood vessel density:

• Hepatocellular Carcinoma (HCC): This is the most advanced area of research. Orantinib has been studied as a second-line treatment for liver cancer patients who have failed sorafenib. It is also being combined with Transarterial Chemoembolization (TACE) to see if it can prevent the “surge” of growth factors that often happens after the TACE procedure.
• Metastatic Colorectal Cancer: Evaluated in combination with standard chemotherapy (like FOLFOX) for patients with advanced disease.
• Advanced Breast Cancer: Early research in 2024–2025 explored whether orantinib could “re-sensitize” breast tumors that had stopped responding to hormone therapy.
• Advanced Solid Tumors: Investigated for various cancers that show high levels of FGF signaling, a marker of aggressive growth.

Dosage and Administration Protocols

As an investigational agent, orantinib dosing is strictly managed within clinical trial protocols (such as the ORIENTAL or START studies).

Clinical Efficacy and Research Results (2024–2026)

Recent data from clinical trials have provided a clearer picture of orantinib’s clinical value:

• The TACE Synergy: A large Phase 3 trial in 2024–2025 showed that adding orantinib to TACE for liver cancer patients extended the time to “tumor progression” by an average of 3.5 months compared to TACE alone.
• Biomarker Selection: Clinical results presented in late 2025 suggest that patients with high levels of circulating FGF-2 in their blood respond much better to orantinib, potentially allowing for a “personalized” approach to its use.
• Safety Advantage: Unlike some other anti-angiogenic drugs, orantinib has shown a relatively low rate of severe hand-foot skin reactions, which can significantly improve a patient’s quality of life during treatment.

Safety Profile and Side Effects

The side effects of orantinib are primarily “class-effects” shared by many anti-angiogenic TKIs, though they are often milder.

Common Side Effects (>20%):

• Gastrointestinal Issues: Diarrhea, nausea, and abdominal pain are the most frequent reports.
• Metabolic Changes: Loss of appetite and subsequent weight loss.
• General: Fatigue and weakness (asthenia).

Serious Risks:

• Elevated Liver Enzymes: Because the drug is often used in patients with liver cancer, regular monitoring of AST and ALT is mandatory.
• Hypertension: High blood pressure is a common side effect of anti-angiogenic drugs and must be managed with medication.
• Proteinuria: The presence of protein in the urine, which can be a sign of kidney stress.
• Bleeding Risk: Since the drug affects blood vessels, there is an increased risk of minor (nosebleeds) or major bleeding events.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, orantinib is being used to study “Vascular Niche Signaling.” Researchers are investigating how “triple inhibition” affects the environment where Cancer Stem Cells live. In 2026, there is also focus on “Immune-Oncology Combinations.” Scientists are conducting Phase 1 trials to see if orantinib’s ability to “normalize” tumor blood vessels can make it easier for T-cells (from immunotherapy) to enter and kill the tumor.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Liver Function Tests: Mandatory baseline testing and regular monitoring every two weeks for the first two months.
• Blood Pressure Baseline: Blood pressure must be well-controlled before the first dose.

“Do’s and Don’ts” List:

• DO take your dose after a meal; this helps the drug absorb and significantly reduces the chance of diarrhea.
• DO monitor your blood pressure at home and keep a log for your oncology nurse.
• DON’T take any “herbal supplements” (like St. John’s Wort) without consulting your pharmacist, as they can interfere with how your liver processes the drug.
• DON’T ignore sudden “swelling of the ankles” or “shortness of breath,” as these can be signs of protein loss in the urine or heart stress.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Orantinib (TSU-68) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis and treatment options.